| Literature DB >> 33718328 |
Hannah B L Jones1, Raphael Heilig1, Roman Fischer1, Benedikt M Kessler1, Adán Pinto-Fernández1.
Abstract
The potency and selectivity of a small molecule inhibitor are key parameters to assess during the early stages of drug discovery. In particular, it is very informative for characterizing compounds in a relevant cellular context in order to reveal potential off-target effects and drug efficacy. Activity-based probes are valuable tools for that purpose, however, obtaining cellular target engagement data in a high-throughput format has been particularly challenging. Here, we describe a new methodology named ABPP-HT (high-throughput-compatible activity-based protein profiling), implementing a semi-automated proteomic sample preparation workflow that increases the throughput capabilities of the classical ABPP workflow approximately ten times while preserving its enzyme profiling characteristics. Using a panel of deubiquitylating enzyme (DUB) inhibitors, we demonstrate the feasibility of ABPP-HT to provide compound selectivity profiles of endogenous DUBs in a cellular context at a fraction of time as compared to previous methodologies.Entities:
Keywords: activitomics; activity-based probes; chemical biology; deubiquitylating enzymes; drug discovery; pharmacology; proteomics; ubiquitin
Year: 2021 PMID: 33718328 PMCID: PMC7947856 DOI: 10.3389/fchem.2021.640105
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.221